Phase 3 N=23 Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department
Acute Musculoskeletal Disease · Sprains · Sprains and Strains
Primary: Change in Numerical Pain Rating Scale — 2.9; 2.1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
Phase 3 N=1,078 A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Chronic Spontaneous Urticaria
Primary: Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult Subjects — -19.218; -20.312; -19.632; -9.221 Scores on a scale — p=<.0001
Phase 3 N=892 Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Atherosclerotic Cardiovascular Disease · Atherosclerotic Cardiovascular Disease Risk Equivelents · Elevated Low Density Lipoprotein Cholesterol
Primary: Percentage Change in LDL-C From Baseline to Day 270 — -37.3; -37.6; -5.4 percent change from baseline in LDL-C — p=<0.001
Phase 3 N=47 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 0; 81.3 percentage of participants — p=<0.001
Phase 3 N=551 A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy
Painful Diabetic Neuropathy
Primary: Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase — -1.9; -2.2; -2.4 units on a scale — p==0.0410
Phase 3 N=485 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma
Asthma
Primary: Stage 1: Percentage of Participants Achieving Device Mastery — 94.4; 86.9 percentage of participants — p=<0.001
Phase 3 N=17 A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Diseases (PID)
Primary: Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2 — 8.56 grams per liter (g/L)
Phase 3 N=393 Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment — 20.6; 9.7 Months
Phase 3 N=30,415 A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
SARS-CoV-2
Primary: Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose — 744; 55 Participants — p=<.0001
Phase 3 N=780 Intermittent Preventive Treatment of Malaria in Schoolchildren
Malaria · Intermittent Preventive Treatment
Primary: Risk of Parasitaemia (Unadjusted by Genotyping) — 23; 87; 164; 147 Participants
Phase 3 N=288 L-PZQ ODT in Schistosoma Infected Children
Schistosomiasis
Primary: Cohort 1a and Cohort 1b: Number of Participants With Clinical Cure Determined by Kato-Katz Method — 86; 39 Participants
Phase 3 N=51 Perioperative Patient Skin Antiseptic Preparation Evaluation
Surgical Site Infection
Primary: Surgical Site Infection Occurrence — 0; 1 Participants
Phase 3 N=307 A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Parkinson Disease
Primary: Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time — -1.93; -0.88 Hours — p=<.0001
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants